SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer - Trial NCT06394492
Access comprehensive clinical trial information for NCT06394492 through Pure Global AI's free database. This Phase 3 trial is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and is currently Not yet recruiting. The study focuses on Ovarian Cancer. Target enrollment is 440 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Timeline & Enrollment
Phase 3
May 31, 2024
Dec 31, 2026
Primary Outcome
Progression-free Survival (PFS) assessed by site investigator as per RECIST 1.1
Summary
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy
 and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with
 platinum-resistant recurrent epithelial ovarian cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06394492
Non-Device Trial